Year: 2026
Type: editorial
Abstract: vaccine platforms, and mechanistic insights that underlie the induction of more effective antitumor immune responses. Collectively, these articles highlight the importance of a deeper understanding of tumor-immune interactions for vaccine design, rational combinations with other therapeutic modalities, progress of diverse vaccine approaches, and clinical trials in various cancer types.Together, the contributions in this collection illustrate a shift toward precision vaccine strategies tailored to individual tumor and immune contexts. This Research Topic reflects a field transitioning from experimental promise to translational reality in diverse cancer types.Triple-negative breast cancer (TNBC) is known as an aggressive and heterogenous subtype prone to antigen-loss escape and inconsistent responses to immunotherapy (8)(9)(10)(11). Lee et al.describe the development of "TNBCvax," a multivalent peptide vaccine targeting TOP2A, HIF-1α, and IGF-1R for immunoprevention. The authors evaluate the vaccine in both syngeneic tumor graft and spontaneous genetically engineered TNBC murine models, demonstrating significant inhibition of tumor growth and delayed tumor onset compared with adjuvant controls. In several comparisons, the multivalent formulation outperformed single-antigen vaccines, supporting the rationale for broader antigen coverage. Mechanistically, TNBCvax induced robust Th1-skewed immune responses, as shown by increased IFN-γ production, enhanced CD8⁺ T cell infiltration, and elevated cytotoxic markers, such as granzyme B and TNF-α within tumors. The vaccine also promoted central memory T cell populations, suggesting potential durability of immune protection.Overall, this study provides preclinical evidence that multivalent vaccination can mitigate tumor heterogeneity and enhance antitumor immunity against TNBC. Future work will need to address translational considerations, including human antigen prevalence, HLA coverage, and integration with complementary immunotherapies.A key challenge in vaccine development is the identification of optimal antigens, with in silico approaches increasingly used to evaluate and prioritize targets capable of eliciting robust T cell responses. Chao et al. addresses this by integrating advanced computational immunology with structural biology to enhance prediction of T cell receptor (TCR) interactions with peptide-major histocompatibility complex (pMHC) complexes. Precise TCR-pMHC recognition underpins effective T cell activation, which is essential for vaccine-mediated tumor eradication and longterm immunological memory. Building on breakthroughs in protein structure prediction, such as AlphaFold 3, the authors demonstrate how deep learning-driven modeling can distinguish immunogenic epitopes from non-functional sequences in silico, offering a scalable alternative to labor-intensive experimental methods. Their findings highlight both the promise and current limitations of artificial intelligence (AI) and machine learning (ML) tools in guiding antigen selection, TCR specificity prediction, and the design of high-affinity T cell-based therapies. By providing a computational framework to rationally prioritize vaccine targets and optimize T cell engagement, this perspective helps integrate mechanistic insights with the broader goals of personalized vaccine development and precision immunotherapy. Together, the contributions in this Research Topic underscore how therapeutic cancer vaccines are moving beyond proof-of-concept toward increasingly sophisticated, mechanism-guided interventions that can be tailored to distinct tumor ecosystems and clinical settings. By spanning preclinical model development, computational antigen discovery, and disease-specific translational advances, these studies collectively chart a roadmap for integrating vaccination into multi-modal immunotherapy strategies. Continued progress will depend on strengthening the dialogue between basic, computational, and clinical research, but the work assembled here offers a compelling glimpse of how rationally designed cancer vaccines may soon become integral to personalized cancer care.
Source: Frontiers in Immunology
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7154059524